Cardiometabolic syndrome increases the risk for cardiovascular disease in people who are obese and have high blood pressure and also causes significant and rapidly progressive kidney disease. Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic ...Saturday, 27 April 2013
Cardiometabolic Syndrome Could be Treated by Epoxide Hydrolase Inhibition and Thiazolidinediones
Cardiometabolic syndrome increases the risk for cardiovascular disease in people who are obese and have high blood pressure and also causes significant and rapidly progressive kidney disease. Scientists at the Medical College of Wisconsin and the University of California at Davis, led by Dr. John Imig and Dr. Bruce Hammock have determined the synergistic actions of inhibiting soluble epoxide hydrolase (sEH) with tAUCB (trans-4-(4-[3-adamantan-1-yl-ureid]-cyclohexyloxy)-benzoic ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment